Drug interactions between Miradon and Zamadol
| Results for the following 2 drugs: |
|---|
| Miradon (anisindione) |
| Zamadol (tramadol) |
Interactions between your selected drugs
anisindione ↔ tramadol
Applies to:Miradon (anisindione) and Zamadol (tramadol)
MONITOR: Coadministration with tramadol may potentiate the hypoprothrombinemic effect of warfarin. There have been rare reports of elevated prothrombin time or INR and bleeding in warfarin patients taking tramadol, and a return to normal anticoagulation following its discontinuation. The exact mechanism is unknown but may be related to reduced activity of CYP450 2D6, which can lead to increased plasma concentrations of tramadol. In a retrospective analysis of 17 cases of suspected interaction between tramadol and warfarin that were reported to the Swedish Adverse Drug Reactions Advisory Committee between 1995 and 2003, INR increases were observed between 1.5 to 60 days following initiation of tramadol therapy (mean 13 days). The recorded INR values ranged from 3.4 to greater than 8.5, and bleeding complications occurred in 6 patients (35%). In cases where follow-up information was available, INR values decreased within 1 to 11 days following tramadol withdrawal. In ten cases where genotypes were available for known polymorphisms of several CYP450 isoenzymes that are associated with reduced or absent enzyme activities, seven patients were found to carry a defective CYP450 2D6 allele. A further patient received concomitant drug treatments that may have resulted in CYP450 2D6 inhibition. Although not statistically significant, this finding suggests a higher prevalence of defective alleles compared to the general Swedish population average of 42.2%.
MANAGEMENT: Given the potential for interaction and the high degree of interpatient variability with respect to warfarin metabolism, patients should be closely monitored during concomitant therapy with tramadol. The INR should be checked frequently and warfarin dosage adjusted accordingly, particularly following initiation, discontinuation or change of dosage of tramadol in patients who are stabilized on their warfarin regimen. The same precaution may be applicable during therapy with other oral anticoagulants, although clinical data are lacking. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
